查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1988428

遺傳性性腺瘤性息肉症治療市場：依治療方法、給藥途徑、通路、最終用戶和適應症分類－2026-2030年全球市場預測

Familial Adenomatous Polyposis Treatment Market by Treatment Type, Route Of Administration, Distribution Channel, End User, Indication - Global Forecast 2026-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年遺傳性腺瘤性息肉症治療市場價值為 12 億美元，預計到 2025 年將成長至 12.9 億美元，複合年成長率為 7.47%，到 2030 年將達到 18.6 億美元。

主要市場統計數據
基準年 2024 12億美元
預計年份：2025年 12.9億美元
預測年份 2030 18.6億美元
複合年成長率 (%) 7.47%

基因突破和綜合護理模式正在推動遺傳性性腺瘤性息肉病治療的發展：塑造患者管理的未來。

遺傳性性腺瘤性息肉症（FAP）是一種遺傳性疾病，其特徵是結腸和直腸上出現數百至數千個腺瘤性息肉，若不治療，幾乎肯定會發展成惡性腫瘤。本文深入探討了FAP的遺傳基礎。 APC抑癌基因的突變會導致早期息肉形成，並加速其發展為大腸直腸癌。鑑於早期病變通常無症狀，且癌症風險極高，因此早期診斷和風險評估的重要性不容忽視。

創新基因治療技術和以患者為中心的治療方法為遺傳性息肉症治療帶來了變革性變化。

過去十年間，科學突破與技術創新相輔相成，從根本上重塑了家族性腺瘤性息肉症（FAP）的治療模式。其中，精準醫療方法特別突出，它利用基因譜分析對患者風險進行分層，並據此最佳化治療方法。基因編輯技術，例如CRISPR/Cas系統，已從臨床前模型發展到早期人體臨床試驗，展現出直接矯正致病性APC突變的潛力。同時，單株抗體設計和標靶遞送系統的進步，使得生物製藥能夠更精準地靶向腫瘤通路，減少脫靶效應，並提高耐受性。

2025年美國關稅對遺傳性性腺瘤性息肉症（FAP）治療供應鏈的綜合影響：進入趨勢與成本結構分析

2025年，美國對進口醫療設備和藥品原料徵收的新關稅措施，正對家族性腺瘤性息肉病（FAP）的治療供應鏈施加多方面的壓力。影響內視鏡系統、專用內視鏡配件和診斷試劑的關稅，導致醫療機構採購成本增加，給公共和私營部門都帶來了預算挑戰。非類固醇消炎劑和生物製藥的藥品原料也受到類似影響，導致生產成本上升。在某些報銷框架下，這些成本可能會轉嫁給支付方和病患。

揭示了治療方法、給藥途徑、分銷管道、最終用戶畫像和具體適應症等方面的關鍵細分見解。

對治療方法方案細分的詳細分析揭示了多種治療方案，這些方案根據疾病進展階段和患者特徵量身定做。聯合治療通訊協定結合多種藥物，協同抑制腺瘤生長；內視鏡監測則可透過大腸鏡和乙狀結腸鏡進行標靶干預。藥物治療方面，治療方式包括生物製藥，例如旨在糾正APC基因突變的先進基因治療平台，以及靶向息肉發生關鍵訊號通路的單株抗體。非類固醇消炎劑（NSAIDs）分為選擇性COX-2抑制劑和傳統非選擇性NSAIDs，它們透過調節與腫瘤發生相關的發炎級聯反應，提供額外的化學預防作用。對於廣泛性息肉​​患者，手術介入仍然是重要的選擇，手術方式多種多樣，從全結腸切除術到迴腸直腸吻合術聯合切除術。每種手術方式在功能恢復和生活品質（QOL）方面各有優劣。

闡明影響美洲、歐洲、中東和非洲以及亞太地區遺傳性性腺瘤性息肉症治療所引入的關鍵區域趨勢。

區域分析揭示了美洲、歐洲、中東和非洲（EMEA）以及亞太地區在治療啟動模式和戰略重點方面存在顯著差異。在美洲，完善的研究基礎設施和成熟的保險報銷機制支持了先進內視鏡技術和生物目標療法的早期應用。北美領先的學術機構正在主導基因編輯方法的臨床試驗，而偏遠地區的遠端醫療計畫正在改善監測活動和藥物依從性監控。

介紹推動遺傳性性腺瘤性息肉病 (FAP) 治療生態系統創新夥伴關係和競爭地位的關鍵產業參與者。

家族性腺瘤性息肉病（FAP）治療領域的行業相關人員涵蓋眾多公司，例如生物製藥創新者、醫療設備製造商和專業服務供應商。領先的生物技術公司正利用病毒和非病毒遞送載體，推進基因治療候選藥物進入早期臨床試驗，以期矯正APC基因。成熟的製藥公司正持續最佳化其單株抗體研發管線，重點關注能夠調節Wnt訊號通路並減少息肉負荷的新型抗原決定基。非選擇性和COX-2選擇性非類固醇抗發炎藥（NSAIDs）的研發者正在評估旨在提高胃腸道耐受性和減少全身副作用的新一代製劑。

為行業領導者提供切實可行的建議，以改善遺傳性性腺瘤性息肉病 (FAP) 的治療途徑並提高患者的治療效果。

為了最大限度地掌握家族性腺瘤性息肉病（FAP）治療領域的新興機遇，行業領導者應優先投資於先進的基因編輯平台和伴隨診斷技術，以實現精準的患者分層。透過建立國內生產能力和替代採購協議來增強供應鏈韌性，可以減輕外部關稅壓力對關鍵設備和試劑的影響。同時，與支付方建立基於價值的合作模式，可以將報銷獎勵與患者療效而非治療次數掛鉤，從而促進高成本生物製藥和基因療法的永續應用。

遺傳性性腺瘤性息肉症治療研究的嚴格調查方法詳情：包括資料來源、框架和檢驗過程。

本報告的調查方法結合了全面的第一手和第二手研究，確保了研究結果的一致性和深度。第二手研究包括對同行評審文獻、主要胃腸病學和腫瘤學學會發布的臨床指南、監管文件和專利資料庫的深入審查。市場相關資訊與政策分析、行業報告和政府出版刊物進行交叉檢驗，以更全面地了解經濟和監管環境。

遺傳性腺瘤性息肉症治療策略性研究成果摘要：相關人員創新治療方案和提升患者照護的指南

本執行摘要概括了對遺傳性性息肉病 (FAP) 治療進行深入調查後獲得的關鍵見解。從突破性的基因編輯到改良的生物製藥和藥物療法，精準醫療的進步正在革新臨床實踐。同時，內視鏡技術的改進以及與數位醫療的融合正在提升疾病的檢測、後續觀察和患者參與度。 2025 年的價格趨勢凸顯了供應鏈柔軟性和策略採購的重要性，以減輕治療的經濟負擔並維持治療的連續性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章遺傳性性腺瘤性息肉症治療市場（依治療方法）

  • 聯合治療
  • 內視鏡後續觀察
    • 大腸鏡檢查
    • 乙狀結腸鏡檢查
  • 藥物治療
    • 生物製藥
      • 基因治療
      • 單株抗體
    • 非類固醇消炎劑
      • COX-2抑制劑
      • 非選擇性非類固醇抗發炎藥
  • 手術介入
    • 切除術
    • 迴腸直腸吻合術
    • 切除術

第9章：遺傳性性腺瘤性息肉症治療市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下

第10章：遺傳性性腺瘤性息肉症治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章遺傳性腺瘤性息肉症治療市場：依最終用戶分類

  • 居家照護
  • 醫院
  • 專科診所

第12章：遺傳性性腺瘤性息肉症治療市場：依適應症分類

  • 輕度FAP
  • 典型的FAP

第13章遺傳性腺瘤性息肉症治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章遺傳性腺瘤性息肉症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：遺傳性性腺瘤性息肉症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國遺傳性性腺瘤性息肉症治療市場

第17章 中國遺傳性性腺瘤性息肉症治療市場

第18章 競爭格局

  • 2024年市場集中度分析
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2024 年
  • 2024年產品系列分析
  • 基準分析，2024 年
  • Bayer Corporation
  • Biodexa Pharmaceuticals PLC
  • Boston Scientific Corporation
  • Eloxx Pharmaceuticals, Inc.
  • Emtora Biosciences
  • FUJIFILM Holdings Corporation
  • KD Pharma Group
  • Medtronic plc
  • Olympus Corporation
  • Parabilis Medicines
  • Pentax Ricoh Imaging Company, Ltd.
  • Siemens Healthcare Private Limited
  • Thermo Fisher Scientific Inc.
Product Code: MRR-6B0EA0797510

The Familial Adenomatous Polyposis Treatment Market was valued at USD 1.20 billion in 2024 and is projected to grow to USD 1.29 billion in 2025, with a CAGR of 7.47%, reaching USD 1.86 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.20 billion
Estimated Year [2025] USD 1.29 billion
Forecast Year [2030] USD 1.86 billion
CAGR (%) 7.47%

Charting the Evolution of Familial Adenomatous Polyposis Treatment Fueled by Genetic Breakthroughs and Integrated Care Models Shaping Future Patient Management

Familial Adenomatous Polyposis (FAP) emerges as a hereditary condition marked by the development of hundreds to thousands of adenomatous polyps along the colon and rectum, possessing a near certainty of malignancy if unaddressed. This introduction delves into the genetic underpinnings of FAP, where mutations in the APC tumor suppressor gene initiate early polyp formation and drive progression toward colorectal cancer. The imperatives of early diagnosis and risk assessment cannot be overstated given the asymptomatic nature of initial lesions and the elevated cancer risk profile.

Over recent decades, a spectrum of interventions has evolved to mitigate disease progression and improve long term outcomes. Endoscopic surveillance techniques such as colonoscopy and sigmoidoscopy have established themselves as frontline measures to detect and remove adenomas before malignancy ensues. Pharmacologic therapies, encompassing both biologic agents and nonsteroidal anti-inflammatory drugs, have demonstrated success in polyp reduction and delay of surgical intervention.

Surgical interventions remain a cornerstone for patients at high risk or with extensive polyp burden, with options ranging from colectomy to ileorectal anastomosis and proctocolectomy. In parallel, combination approaches leveraging pharmacologic suppression and endoscopic monitoring have emerged as integrated care pathways. Patient-centric models have begun to incorporate digital health solutions that facilitate remote monitoring and adherence tracking, enabling a more proactive management approach. As research advances, next generation gene therapies and monoclonal antibodies promise to redefine treatment paradigms. The following sections will examine how these developments, alongside regulatory shifts and economic factors, are influencing the direction of FAP treatment and shaping strategic priorities for stakeholders across the healthcare ecosystem.

Illuminating Transformative Shifts in Familial Adenomatous Polyposis Treatment Driven by Innovative Gene Therapies Techniques and Patient-Centric Approaches

Over the past decade, the FAP treatment landscape has been fundamentally reshaped by a confluence of scientific breakthroughs and technological innovations. At the forefront are precision medicine approaches that leverage genetic profiling to stratify patient risk and tailor therapeutic regimens accordingly. Gene editing technologies such as CRISPR/Cas systems are advancing from preclinical models toward early human trials, offering the prospect of directly correcting pathogenic APC mutations at their source. Concurrently, advances in monoclonal antibody design and targeted delivery systems are yielding biologic compounds with enhanced specificity for neoplastic pathways, reducing off target effects and improving tolerability.

Endoscopic techniques have also undergone significant refinement, with high definition imaging and virtual chromoendoscopy enhancing polyp detection rates, while minimally invasive instruments facilitate more efficient resections. Integration of artificial intelligence and machine learning into image analysis is accelerating diagnostic accuracy and procedural efficiency. Digital health platforms are enabling continuous patient monitoring and real time data capture, fostering agile responses to treatment responses and adherence challenges.

These developments have collectively shifted FAP management from reactive polypectomy toward proactive disease interception, emphasizing early molecular intervention and personalized surveillance intervals. The emergence of combination protocols blending systemic pharmacotherapies with precision endoscopy is redefining standard of care, driving improved clinical outcomes and setting new benchmarks for long term disease control.

Regulatory frameworks have also adapted to expedite review of breakthrough therapies, with numerous expedited pathways enabling faster patient access to high potential interventions. Funding initiatives by public and private entities are accelerating early stage research, fostering collaborations that bridge academic discovery with commercial development. As these shifts coalesce, the FAP treatment arena is poised for a new era of innovation that harmonizes clinical excellence with operational agility.

Analyzing the Comprehensive Effects of 2025 United States Tariffs on Familial Adenomatous Polyposis Treatment Supply Chains Access Dynamics and Cost Structures

In 2025, newly enacted tariff measures imposed by the United States on imported medical equipment and pharmaceutical components have exerted multifaceted pressures on the FAP treatment supply chain. Tariffs affecting endoscopy systems, specialized endoscopic accessories, and diagnostic reagents have translated into higher acquisition costs for healthcare providers, challenging budgets in both public and private sectors. Pharmaceutical ingredients for nonsteroidal anti-inflammatory drugs and biologics have similarly been impacted, leading to increased production expenses that may be passed along to payers and patients under certain reimbursement frameworks.

These cumulative effects have prompted institutions to reassess procurement strategies, prioritizing suppliers with domestic manufacturing capabilities or tariff exempt status. Some clinical networks are exploring regional partnerships to establish shared warehousing and distribution hubs, mitigating the inflationary impact of cross border levies. Moreover, the anticipated cost headwinds have intensified negotiations with payers to secure value based contracts that align therapeutic reimbursement with clinical outcomes, rather than volume of procedures.

Clinicians and administrators are also evaluating the viability of alternative pharmacologic formulations that rely on locally sourced active compounds to maintain treatment affordability. While these adaptations have helped stabilize operations, persistent tariff uncertainty complicates long term planning and may hinder the adoption of next generation gene therapies that depend on specialized import components.

Patients have felt the downstream effects of these tariff driven cost shifts, encountering higher out of pocket expenses under certain insurance benefit designs. Delays in equipment replacement cycles have in some cases resulted in longer scheduling lead times for endoscopic evaluations, presenting risks for patients awaiting surveillance procedures. To safeguard patient adherence and clinical outcomes, some providers are exploring patient assistance programs and outcome based payment models that distribute financial risk and promote affordability.

Revealing Critical Segmentation Insights Across Treatment Modalities Administration Routes Distribution Channels End User Profiles and Specific Indications

An in-depth examination of treatment type segmentation reveals a diverse therapeutic arsenal tailored to distinct disease stages and patient profiles. Combination therapy protocols integrate multiple pharmacologic agents to synergistically inhibit adenoma growth, while endoscopic surveillance offers targeted interventions through colonoscopy and sigmoidoscopy procedures. Within pharmacologic therapy, biologic modalities encompass advanced gene therapy platforms designed to correct APC mutations, alongside monoclonal antibodies that target key signaling pathways implicated in polyp development. Nonsteroidal anti-inflammatory drugs, subdivided into selective COX-2 inhibitors and traditional nonselective NSAIDs, provide additional chemopreventive benefits by modulating inflammatory cascades associated with neoplastic transformation. Surgical intervention remains a critical option for individuals with extensive polyp burden, with procedures ranging from total colectomy to ileorectal anastomosis and proctocolectomy, each offering distinct trade-offs in terms of functional outcomes and quality of life.

Route of administration further differentiates therapeutic choices, with intravenous infusions employed for certain biologic agents, oral formulations enabling outpatient accessibility for chemopreventive drugs, and subcutaneous injections serving as a convenient delivery method for selected monoclonal therapies. Distribution channel dynamics influence treatment acquisition, as hospital pharmacies maintain institutional inventories for inpatient and outpatient care, online pharmacies offer streamlined ordering and home delivery, and retail pharmacies support community-based dispensing. End users span home care settings that facilitate patient self-administration under remote supervision, hospitals that deliver complex procedural and pharmacologic regimens, and specialty clinics focusing on advanced diagnostics and interventional strategies. Finally, indication specificities distinguish between attenuated FAP presentations, characterized by fewer polyps and later onset, and classic FAP profiles with early, aggressive polyp proliferation, guiding tailored therapeutic pathways across the patient journey.

Illuminating Pivotal Regional Dynamics Shaping Familial Adenomatous Polyposis Treatment Adoption in the Americas Europe Middle East Africa and Asia Pacific

Regional analysis underscores distinct adoption patterns and strategic priorities across the Americas, Europe Middle East Africa (EMEA) and Asia Pacific. In the Americas, robust research infrastructure and established reimbursement frameworks have supported early adoption of advanced endoscopic techniques and targeted biologic therapies. Leading academic centers in North America are spearheading clinical trials for gene editing approaches, while telemedicine initiatives in remote areas have improved surveillance outreach and adherence monitoring.

Within Europe, Middle East and Africa, treatment landscapes exhibit heterogeneity driven by national healthcare policies and resource availability. Western European nations have integrated precision therapeutics within standardized care pathways, whereas certain Middle Eastern and African markets are prioritizing capacity building for endoscopic services and pharmacologic accessibility. Cross-regional collaborations are emerging to harmonize regulatory guidelines, enabling streamlined approvals for innovative agents and equipment.

In the Asia Pacific region, rising awareness of hereditary colorectal disorders is fueling investment in diagnostic services and patient education programs. Governments are incentivizing local production of generic chemopreventive agents and facilitating technology transfer partnerships to enhance access. Infrastructure expansion in Southeast Asia has improved hospital pharmacy networks, while online platforms are increasingly utilized to bridge gaps in distribution. Specialty clinics in key urban centers are consolidating multidisciplinary care teams, reflecting a shift toward integrated management models.

Looking ahead, cross regional knowledge exchange and public private partnerships will be critical to harmonize standards of care and disseminate best practices, ensuring that innovations in FAP management deliver maximum patient benefit on a global scale.

Highlighting Leading Industry Players Driving Innovation Partnerships and Competitive Positioning within the Familial Adenomatous Polyposis Treatment Ecosystem

Industry participants within the FAP treatment landscape encompass a spectrum of biopharmaceutical innovators, medical device manufacturers and specialized service providers. Leading biotechs have advanced gene therapy candidates through early phase studies, harnessing viral and nonviral delivery vectors to target APC gene correction. Established pharmaceutical firms continue to optimize monoclonal antibody pipelines, focusing on novel epitopes that modulate Wnt signaling and reduce polyp burden. Nonselective and COX-2 selective NSAID developers are evaluating next generation formulations aimed at enhancing gastrointestinal tolerability and reducing systemic side effects.

Medical device companies are driving advancements in endoscopic hardware, introducing flexible platforms with integrated high resolution imaging, artificial intelligence assistance and accessory compatibility for streamlined polypectomies. Collaborations between diagnostic specialists and imaging software providers are yielding real time analytics that inform procedural decision making. On the distribution front, pharmacy networks and logistics partners are refining cold chain protocols to support the growing portfolio of temperature sensitive biologics and gene therapy products.

Strategic alliances between biopharma and academic centers are accelerating translational research, while partnerships with contract research organizations are expediting trial operations. Early stage companies have leveraged venture funding to validate proprietary delivery technologies, attracting attention from larger players seeking acquisition or licensing agreements. Furthermore, the pursuit of orphan drug designations and expedited regulatory pathways is incentivizing research investment, with several companies leveraging exclusivity provisions to support long term development programs. Intellectual property strategies and patent litigation trends will shape the competitive landscape as novel therapies progress toward commercialization.

Formulating Actionable Recommendations for Industry Leaders to Improve Access and Enhance Patient Outcomes in Familial Adenomatous Polyposis Treatment

To capitalize on emerging opportunities within the FAP treatment arena, industry leaders should prioritize investment in advanced gene editing platforms and companion diagnostics that enable precise patient stratification. Strengthening supply chain resilience through the development of domestic manufacturing capabilities or alternative sourcing agreements will mitigate the impact of external tariff pressures on critical equipment and reagents. Concurrently, establishing value based collaboration models with payers can align reimbursement incentives with patient outcomes rather than procedural volume, fostering sustainable adoption of high cost biologics and gene therapies.

It is essential to integrate digital health solutions into care pathways, leveraging remote monitoring tools and artificial intelligence driven decision support to enhance adherence, optimize surveillance schedules and reduce the burden on clinical resources. Partnerships with technology providers and data analytics firms can unlock real world evidence that informs continuous improvement and regulatory filings. Engagement with policymakers and industry associations should be intensified to advocate for balanced trade policies and streamlined approval processes, ensuring uninterrupted access to innovative treatments.

In parallel, developing risk management frameworks and scenario planning exercises will equip leadership teams to anticipate regulatory adjustments, tariff shifts and competitive moves. Investing in real time data platforms that offer predictive insights into patient volumes, therapy responses and operational bottlenecks will further enhance strategic resilience. Lastly, cultivating multidisciplinary care networks that unite gastroenterologists, genetic counselors, surgeons and allied health professionals will drive holistic patient management and improve quality of life outcomes.

Detailing the Rigorous Research Methodology of the Familial Adenomatous Polyposis Treatment Study Including Data Sources Frameworks and Validation Processes

The methodology underpinning this report combines comprehensive secondary and primary research to ensure the integrity and depth of insights. Secondary research involved an exhaustive review of peer reviewed literature, clinical guidelines published by leading gastroenterology and oncology societies, regulatory filings and patent databases. Market related intelligence was cross validated with policy analyses, trade reports and government publications to capture the broader economic and regulatory context.

Primary research incorporated structured interviews and surveys with key opinion leaders, including gastroenterologists specializing in hereditary colorectal disorders, surgical oncologists, clinical geneticists and supply chain experts. Additional discussions with hospital administrators, pharmacy directors and payer representatives provided practical perspectives on procurement challenges, reimbursement dynamics and patient access considerations. Data from these interactions were rigorously triangulated with secondary sources to resolve discrepancies and refine thematic conclusions.

An analytical framework guided segmentation by treatment type, route of administration, distribution channel, end user and indication, facilitating targeted insight generation. Regional analyses employed economic and healthcare infrastructure metrics to contextualize adoption patterns. Ethical oversight and patient consent protocols were carefully integrated into primary research activities, ensuring compliance with data privacy regulations and upholding participant confidentiality throughout the study process. Quality control measures included peer reviews by subject matter experts and systematic data verification to uphold factual accuracy. This robust approach ensures that the findings and recommendations reflect a balanced, evidence based understanding of the FAP treatment landscape.

Summarizing Strategic Insights into Familial Adenomatous Polyposis Treatment to Guide Stakeholders in Advancing Therapeutic Innovation and Patient Care

This executive summary distills the critical insights gleaned from a thorough examination of the familial adenomatous polyposis treatment domain. Advances in precision medicine, from gene editing breakthroughs to enhanced biologic and pharmacologic therapies, are revolutionizing clinical practice, while improvements in endoscopic technology and digital health integration are elevating detection, surveillance and patient engagement. The 2025 tariff landscape underscores the necessity of supply chain flexibility and strategic sourcing to preserve treatment affordability and continuity.

Segmentation analysis highlights the diverse modalities and delivery routes that shape tailored care pathways, as well as the pivotal role of distribution channels and end user environments in facilitating accessibility. Regional dynamics reveal a tapestry of healthcare ecosystems, each advancing FAP management in alignment with local priorities and resource capacities. Industry collaboration, characterized by partnerships between biotechs, device manufacturers and academic institutions, is accelerating translational research and fostering a competitive yet cooperative landscape.

Actionable recommendations emphasize the importance of investing in domestic manufacturing, value based contracting, digital platforms and multidisciplinary networks to drive sustainable innovation and enhance patient outcomes. Continuous monitoring of emerging clinical trial results and policy developments will be essential to maintain the relevance of these insights and to inform subsequent updates to the report. By applying these strategic imperatives, stakeholders across the healthcare continuum can navigate evolving challenges and deliver more effective, patient centered solutions for those affected by this hereditary condition.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Familial Adenomatous Polyposis Treatment Market, by Treatment Type

  • 8.1. Combination Therapy
  • 8.2. Endoscopic Surveillance
    • 8.2.1. Colonoscopy
    • 8.2.2. Sigmoidoscopy
  • 8.3. Pharmacologic Therapy
    • 8.3.1. Biologics
      • 8.3.1.1. Gene Therapy
      • 8.3.1.2. Monoclonal Antibodies
    • 8.3.2. Nonsteroidal Anti-Inflammatory Drugs
      • 8.3.2.1. COX-2 Inhibitors
      • 8.3.2.2. Nonselective NSAIDs
  • 8.4. Surgical Intervention
    • 8.4.1. Colectomy
    • 8.4.2. Ileorectal Anastomosis
    • 8.4.3. Proctocolectomy

9. Familial Adenomatous Polyposis Treatment Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Familial Adenomatous Polyposis Treatment Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Familial Adenomatous Polyposis Treatment Market, by End User

  • 11.1. Home Care
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Familial Adenomatous Polyposis Treatment Market, by Indication

  • 12.1. Attenuated FAP
  • 12.2. Classic FAP

13. Familial Adenomatous Polyposis Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Familial Adenomatous Polyposis Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Familial Adenomatous Polyposis Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Familial Adenomatous Polyposis Treatment Market

17. China Familial Adenomatous Polyposis Treatment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2024
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2024
  • 18.3. Product Portfolio Analysis, 2024
  • 18.4. Benchmarking Analysis, 2024
  • 18.5. Bayer Corporation
  • 18.6. Biodexa Pharmaceuticals PLC
  • 18.7. Boston Scientific Corporation
  • 18.8. Eloxx Pharmaceuticals, Inc.
  • 18.9. Emtora Biosciences
  • 18.10. FUJIFILM Holdings Corporation
  • 18.11. KD Pharma Group
  • 18.12. Medtronic plc
  • 18.13. Olympus Corporation
  • 18.14. Parabilis Medicines
  • 18.15. Pentax Ricoh Imaging Company, Ltd.
  • 18.16. Siemens Healthcare Private Limited
  • 18.17. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2018-2030 (USD THOUSAND)
  • FIGURE 2. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 5. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 6. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 7. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 8. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 9. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 10. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 11. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 12. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2018-2030 (USD THOUSAND)
  • FIGURE 13. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2018-2030 (USD THOUSAND)

LIST OF TABLES

  • TABLE 1. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2018-2030 (USD THOUSAND)
  • TABLE 2. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 3. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 4. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 5. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 6. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 7. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 8. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 9. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
  • TABLE 10. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COLONOSCOPY, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 11. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COLONOSCOPY, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 12. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COLONOSCOPY, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 13. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SIGMOIDOSCOPY, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 14. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SIGMOIDOSCOPY, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 15. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SIGMOIDOSCOPY, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 16. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 17. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 18. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 19. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
  • TABLE 20. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 21. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 22. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 23. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
  • TABLE 24. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 25. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 26. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 27. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 28. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 29. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 30. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 31. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 32. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 33. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
  • TABLE 34. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COX-2 INHIBITORS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 35. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COX-2 INHIBITORS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 36. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COX-2 INHIBITORS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 37. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSELECTIVE NSAIDS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 38. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSELECTIVE NSAIDS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 39. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSELECTIVE NSAIDS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 40. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 41. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 42. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 43. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
  • TABLE 44. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COLECTOMY, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 45. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COLECTOMY, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 46. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COLECTOMY, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 47. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ILEORECTAL ANASTOMOSIS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 48. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ILEORECTAL ANASTOMOSIS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 49. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ILEORECTAL ANASTOMOSIS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 50. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PROCTOCOLECTOMY, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 51. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PROCTOCOLECTOMY, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 52. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PROCTOCOLECTOMY, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 53. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
  • TABLE 54. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 55. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 56. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 57. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 58. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 59. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 60. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 61. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 62. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 63. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 64. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 65. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 66. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 67. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 68. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 69. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 70. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 71. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 72. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 73. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 74. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 75. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 76. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 77. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 78. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 79. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 80. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 81. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 82. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 83. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
  • TABLE 84. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ATTENUATED FAP, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 85. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ATTENUATED FAP, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 86. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ATTENUATED FAP, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 87. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY CLASSIC FAP, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 88. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY CLASSIC FAP, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 89. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY CLASSIC FAP, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 90. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 91. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2030 (USD THOUSAND)
  • TABLE 92. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 93. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
  • TABLE 94. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
  • TABLE 95. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
  • TABLE 96. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
  • TABLE 97. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
  • TABLE 98. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
  • TABLE 99. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 100. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 101. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
  • TABLE 102. NORTH AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 103. NORTH AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 104. NORTH AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
  • TABLE 105. NORTH AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
  • TABLE 106. NORTH AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
  • TABLE 107. NORTH AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
  • TABLE 108. NORTH AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
  • TABLE 109. NORTH AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
  • TABLE 110. NORTH AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 111. NORTH AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 112. NORTH AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
  • TABLE 113. LATIN AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 114. LATIN AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 115. LATIN AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
  • TABLE 116. LATIN AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
  • TABLE 117. LATIN AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
  • TABLE 118. LATIN AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
  • TABLE 119. LATIN AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
  • TABLE 120. LATIN AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
  • TABLE 121. LATIN AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 122. LATIN AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 123. LATIN AMERICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2030 (USD THOUSAND)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
  • TABLE 135. EUROPE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 136. EUROPE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 137. EUROPE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
  • TABLE 138. EUROPE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
  • TABLE 139. EUROPE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
  • TABLE 140. EUROPE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
  • TABLE 141. EUROPE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
  • TABLE 142. EUROPE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
  • TABLE 143. EUROPE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 144. EUROPE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 145. EUROPE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
  • TABLE 146. MIDDLE EAST FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 147. MIDDLE EAST FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 148. MIDDLE EAST FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
  • TABLE 149. MIDDLE EAST FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
  • TABLE 150. MIDDLE EAST FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
  • TABLE 151. MIDDLE EAST FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
  • TABLE 152. MIDDLE EAST FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
  • TABLE 153. MIDDLE EAST FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
  • TABLE 154. MIDDLE EAST FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 155. MIDDLE EAST FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 156. MIDDLE EAST FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
  • TABLE 157. AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 158. AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 159. AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
  • TABLE 160. AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
  • TABLE 161. AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
  • TABLE 162. AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
  • TABLE 163. AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
  • TABLE 164. AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
  • TABLE 165. AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 166. AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 167. AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
  • TABLE 168. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 169. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 170. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
  • TABLE 171. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
  • TABLE 172. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
  • TABLE 173. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
  • TABLE 174. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
  • TABLE 175. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
  • TABLE 176. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 177. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 178. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
  • TABLE 179. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2030 (USD THOUSAND)
  • TABLE 180. ASEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 181. ASEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 182. ASEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
  • TABLE 183. ASEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
  • TABLE 184. ASEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
  • TABLE 185. ASEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
  • TABLE 186. ASEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
  • TABLE 187. ASEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
  • TABLE 188. ASEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 189. ASEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 190. ASEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
  • TABLE 191. GCC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 192. GCC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 193. GCC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
  • TABLE 194. GCC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
  • TABLE 195. GCC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
  • TABLE 196. GCC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
  • TABLE 197. GCC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
  • TABLE 198. GCC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
  • TABLE 199. GCC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 200. GCC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 201. GCC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
  • TABLE 202. EUROPEAN UNION FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 203. EUROPEAN UNION FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 204. EUROPEAN UNION FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
  • TABLE 205. EUROPEAN UNION FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
  • TABLE 206. EUROPEAN UNION FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
  • TABLE 207. EUROPEAN UNION FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
  • TABLE 208. EUROPEAN UNION FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
  • TABLE 209. EUROPEAN UNION FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
  • TABLE 210. EUROPEAN UNION FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 211. EUROPEAN UNION FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 212. EUROPEAN UNION FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
  • TABLE 213. BRICS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 214. BRICS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 215. BRICS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
  • TABLE 216. BRICS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
  • TABLE 217. BRICS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
  • TABLE 218. BRICS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
  • TABLE 219. BRICS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
  • TABLE 220. BRICS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
  • TABLE 221. BRICS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 222. BRICS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 223. BRICS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
  • TABLE 224. G7 FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 225. G7 FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 226. G7 FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
  • TABLE 227. G7 FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
  • TABLE 228. G7 FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
  • TABLE 229. G7 FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
  • TABLE 230. G7 FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
  • TABLE 231. G7 FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
  • TABLE 232. G7 FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 233. G7 FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 234. G7 FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
  • TABLE 235. NATO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 236. NATO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 237. NATO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
  • TABLE 238. NATO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
  • TABLE 239. NATO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
  • TABLE 240. NATO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
  • TABLE 241. NATO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
  • TABLE 242. NATO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
  • TABLE 243. NATO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 244. NATO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 245. NATO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
  • TABLE 246. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 247. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2018-2030 (USD THOUSAND)
  • TABLE 248. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 249. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
  • TABLE 250. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
  • TABLE 251. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
  • TABLE 252. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
  • TABLE 253. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
  • TABLE 254. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUSAND)
  • TABLE 255. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
  • TABLE 256. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 257. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD THOUSAND)
  • TABLE 258. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2018-2030 (USD THOUSAND)
  • TABLE 259. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 260. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2030 (USD THOUSAND)
  • TABLE 261. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD THOUSAND)
  • TABLE 262. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD THOUSAND)
  • TABLE 263. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2030 (USD THOUSAND)
  • TABLE 264. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD THOUSAND)
  • TABLE 265. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD THOUS